ISIS Delivers Mixed SMN Data and Phase III Program Details at AAN: ISISâ stock has sold off due to mixed data for SMN-Rx in infants and children. There is not a lot of new data and most of it shows a benefit. However, the negative focus has been on patient deaths that were not drug[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.